Prosecution Insights
Last updated: November 04, 2026
Application No. 18/702,249

LIQUID COMPOSITION CONTAINING A COMBINATION OF VITAMINS A, D, E AND K IN A LIQUID MATRIX

Non-Final OA §103§112
Filed
Apr 17, 2024
Priority
Oct 19, 2021 — EU 21203508.3 +1 more
Examiner
HOERNER, PAUL ELLSWORTH
Art Unit
1611
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Llpoid GmbH
OA Round
1 (Non-Final)
51%
Grant Probability
Moderate
1-2
OA Rounds
1y 1m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 51% of resolved cases
51%
Career Allowance Rate
42 granted / 83 resolved
-9.4% vs TC avg
Strong +62% interview lift
Without
With
+62.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
51 currently pending
Career history
131
Total Applications
across all art units

Statute-Specific Performance

§101
1.6%
-38.4% vs TC avg
§103
48.3%
+8.3% vs TC avg
§102
12.1%
-27.9% vs TC avg
§112
21.6%
-18.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 83 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority Acknowledgment is made of applicant’s claim for foreign priority under 35 U.S.C. 119 (a)-(d). Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Election/Restrictions Applicant’s election of Group I drawn to a liquid composition in the reply filed on 17 July 2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Claims 15 and 17-18 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 17 July 2026. Applicant’s election of retinyl palmitate as the species of component a), vitamin D3 as the species of component b), tocopherol acetate as the species of component c), vitamin K1 as the species of component d), glycerin as the species of component e), MCT oil as the species of component f), phosphatidyl choline as the species of component h), β-carotene as the species of component i), and a species of composition further comprising zinc bisglycinate in the reply filed on 17 July 2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Claims 1-14 and 16 are examined on the merits herein. Claim Rejections - 35 USC § 112(d) The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 3-4 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claims 3-4 recite the composition of claim 1, wherein the total amount of components a) to d) is in the range of 0.2 to 20% by weight. However, claim 1 recites the total amount of components of a) to d) is at least 0.3% by weight. As such, claims 3-4 fail to include all of the limitations of the claim upon which they depend. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. For examination purposes, claims 3-4 are interpreted as reciting the total amount of components a) to d) in the range of 0.3 to 20% by weight. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-8, 12-14, and 16 are rejected under 35 U.S.C. 103 as being unpatentable over Shade et al. (US 10,722,465 cited on Applicant’s IDS filed 6 March 2025) in view of Blanke et al. (US 2010/0183770 cited on Applicant’s IDS filed 6 March 2025). The instant claims are drawn to a liquid composition comprising: 0.001 to 0.4% by weight vitamin A; 0.00005 to 0.3% by weight vitamin D3 (Applicant’s elected species); 0.1 to 19% by weight vitamin E; 0.001 to 0.4% by weight vitamin K1 (Applicant’s elected species); 40 to 95% by weight of at least one water miscible polyol, more specifically glycerin (Applicant’s elected species); 1 to 40% by weight of at least one edible triglyceride, more specifically MCT oils (Applicant’s elected species); 3 to 30% by weight water; 0.5 to 10% by weight of a phospholipid composition, more specifically phosphatidylcholine (Applicant’s elected species); and 0.01 to 10% by weight β-carotene (Applicant’s elected species), wherein the total amount of components a) to d) is in the range of 0.3 to 20% by weight, wherein the liquid composition is translucent. As thus summarized, the instant invention reads on claims 1-7 and 13. Shade et al. teach transparent liquid compositions of vitamins (Abstract), further teaching in Examples 1 and 2 (Cols. 8-9) a composition comprising: 0.062% vitamin A; 0.019% vitamin D3; 1.77% vitamin E; 0.0014% vitamin K1; 60.98% glycerin; citrus oil; water; phosphatidylcholine; and 0.010% β-carotene, wherein the total amounts of components a) to d) is 1.85%. As such, Shade et al. teach a liquid composition comprising 0.001 to 0.4% by weight vitamin A; 0.00005 to 0.3% by weight vitamin D3; 0.1 to 19% by weight vitamin E; 0.001 to 0.4% by weight vitamin K1; 40 to 95% by weight glycerin; and 0.01 to 10% by weight β-carotene, wherein the total amount of components a) to d) is in the range of 0.3 to 20% by weight, wherein the liquid composition is translucent. The composition of Shade et al. differs from the instantly claimed invention in the following ways: the composition of Shade et al. does not comprise MCT oil; Shade et al. are silent as to the amount of the edible triglyceride in the composition; Shade et al. are silent as to the amount of water in the composition; and Shade et al. are silent as to the amount of phosphatidylcholine in the composition. Yet, as to 1: Shade et al. further teach the oil component of the composition being selected from citrus oil and MCT oil (Col. 6 lines 15-18). Therefore, it would have been prima facie obvious to a person having ordinary skill in the art before the effective filing date of the claimed invention to have modified the composition of Shade et al. to include MCT oil. It would have been obvious to substitute one oil taught to be suitable for use in the vitamin compositions for another to obtain the predictable result of a vitamin composition, with a reasonable expectation of success. And, as to 2-4: Shade et al. further teach the emulsifiers(TGPS and phosphatidylcholine) and oil being added to provide the desired physical structures in the nanoemulsion (Col. 8 lines 66-67; col. 9 lines 5-20), additionally teaching that the desired physical structures within the nanoemulsion lead to improved oral delivery (Col. 6 lines 23-33), indicating to one of ordinary skill in the art that the concentrations of the oil and phosphatidylcholine are result effective variables, determining the physical structure of the nanoemulsion, and thus the oral delivery efficacy. Blanke et al. also teach emulsions for the delivery of vitamins A, D3, E, and K (Par. [0001]) including an edible triglyceride oil (Pars. [0028-29]) in an amount of about 40 to 60% by weight (Par. [0037]); and an emulsifier comprising a caseinate (Abstract) in an amount of 2.5 to 4.5% by weight (Par. [0035]), indicating to one of ordinary skill in the art suitable ranges for the oil and emulsifier in the composition of Shade et al. to be further optimized. And, as discussed by MPEP 2144.05, “[g]enerally, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical” (see also In re Aller (220 F.2d 454)): “where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation…” Indeed, as further discussed by the court, “[s]uch experimentation is no more than the application of the expected skill of the [ordinarily skilled artisan] and failure to perform such experiments would, in our opinion, show a want of the expected skill”; see also In re Peterson, 315 F.3d at 1325 (Fed. Cir. 2005): “[t]he normal desire of scientists or artisans to improve upon what is already generally known provides the motivation to determine where in a disclosed set of percentage ranges is the optimum combination of percentages” and “[o]nly if the ‘results of optimizing a variable’ are ‘unexpectedly good’ can a patent be obtained for the claimed critical range” (quoting In re Antonie (559 F.2d 618 (CCPA 1977))). In the instant case, the concentrations of MCT oil and phosphatidylcholine are clearly result-effective variables, determining the physical structure of the nanoemulsion. Accordingly, it would have been customary for an artisan of ordinary skill in the art to determine the optimal concentrations of MCT oil and phosphatidylcholine in order to best achieve the desired results. Shade et al. further teach the composition comprising approximately 1.25 mL of ethanol and 1.6 mL of glycerin (Col. 8 lines 63-64), as calculated by examiner, and adding water until a total volume of 5mL (Col. 9 lines 1-2). As water is added to bring the composition to a fixed volume, optimization of the amount of oil in the composition would necessarily result in the optimization of the amount of water in the composition. Based on all of the foregoing, claims 1-7 and 13 are rejected as prima facie obvious. Applicant’s elected species are drawn to the composition of claim 1, wherein the vitamin A ester is retinyl palmitate and the vitamin E ester is tocopherol acetate. Shade et al. do not teach retinyl palmitate or tocopherol acetate. However, Blanke et al. teach the vitamin A and vitamin E forms preferably being retinyl palmitate and tocopherol acetate (Par. [0018]). Therefore, it would have been prima facie obvious to a person having ordinary skill in the art before the effective filing date of the claimed invention to have modified the composition of Shade et al. to include retinyl palmitate and tocopherol acetate as taught by Blanke et al. It would have been obvious to substitute forms of vitamins A and E taught to be suitable for oral administration for each other to obtain the predictable result of an oral composition including vitamin A and vitamin E, with a reasonable expectation of success. As such, Applicant’s elected species are rejected as prima facie obvious. Claim 8 is drawn to the composition of claim 1, wherein components a), b), c), d), and i) are essentially present in dissolved form. Shade et al. further teach vitamin A (Col. 1 line 24), vitamin D3 (Col. 1 line 34), vitamin E (Col. 1 line 43), vitamin K1 (Col. 1 line 62), and β-carotene (Col. 1 lines 66-67) as being oil soluble, additionally teaching these vitamins being combined with the oil (Col. 9 lines 18-19), indicating that the components a), b), c), d), and i) are essentially present in dissolved form. As such, claim 8 is rejected as prima facie obvious. Claim 12 is drawn to the composition of claim 1, wherein the weight ratio of the phosphatidylcholine to the triglyceride is in the range of 1:20 to 1:1. Routine optimization of the amount of phosphatidylcholine and MCT oil would necessarily result in the optimization of the ratio between phosphatidylcholine and MCT oil. Further, the amounts of oil and emulsifier taught by Blanke et al. correspond to a phosphatidylcholine to MCT oil weight ratio of 1:24 to 1:8.9, overlapping with the instantly claimed range. As such, claim 12 is rejected as prima facie obvious. Claim 14 is drawn to the composition of claim 1 which has at least one of the following features: the weight ratio of component f) to the total weight of components a), b), c), d), and i) is in the range of 1:1 to 100:1; the phospholipid composition contains phosphatidylcholine in an amount of at least 45% by weight, based on the total weight of the phospholipid composition; the liquid composition is characterized in that a dilution of the liquid composition in deionized water at 25°C and at a concentration of 1% by weight forms droplets having a Z average particle diameter of at most 500 nm; and the liquid composition additionally contains a water-soluble organic antioxidant. As to A), optimization of the amount of MCT oil in the composition would necessarily result in the optimization of the weight ratio of the MCT oil to components a), b), c), d), and i). Further, based on the suitable oil amount taught by Blanke et al. and the amount of components a), b), c), d), and i), the ratio of MCT oil to vitamins ranges from 21.5:1 to 32.3:1 as calculated by examiner, overlapping with the instantly claimed range. As to B), Shade et al. further teach utilizing a combination of phospholipids comprising at least 30% phosphatidylcholine by weight (Claim 27), overlapping with the instantly claimed range. As to C), Shade et al. further teach the emulsions having a maximum particle size of 100 nm (Col. 6 lines 23-33), overlapping with the instantly claimed range. And, as to D), Shade et al. further teach in Example 1 the composition comprising vitamin C (Col 8 line 56) i.e., a water-soluble organic antioxidant. As such, claim 14 is rejected as prima facie obvious. Claim 16 is drawn to formulation comprising the composition according to claim 1 and a carrier or vehicle, which is a formulation for oral administration. Shade et al. further teach the composition for delivery orally (Col. 4 lines 11-14) and the composition additionally comprising a flavoring (Col. 8 lines 32-34). Blanke et al. teach using the supplement composition for fortification of a product such as milk or juice (Par. [0007]), reading on a carrier. Therefore, it would have been prima facie obvious to a person having ordinary skill in the art before the effective filing date of the claimed invention to have modified the composition of Shade et al. by utilizing it to fortify a product such as milk or juice. It would have been obvious to combine the known oral supplement composition with the known use of oral supplement compositions for fortifying products to yield the predictable result of a palatable composition for oral delivery of vitamins, with a reasonable expectation of success. As such, claim 16 is rejected as prima facie obvious. Claims 9-11 are rejected under 35 U.S.C. 103 as being unpatentable over Shade et al. and Blanke et al. as applied to claims 1-8, 12-14, and 16 above, and further in view of Higdon et al. (“Zinc”, Linus Pauling Institute, 2019) and Gandia et al. (Int J Vitam Nutr Res, 2007, Vol. 77, 243-248). The teachings of Shade et al. and Blanke et al. have been set forth above. Claims 9-10 are drawn to the composition of claim 1, further comprising zinc bisglycinate (Applicant’s elected species). Shade et al. and Blanke et al. do not teach the composition comprising a zinc compound. Higdon et al. teach that the bioavailability of vitamin B9 is dependent on zing (“Folate” on pg. 5), further teaching that zinc is required for a protein necessary for transporting vitamin A in the blood, and zinc deficiency being associated with a decreased release of vitamin A from the liver (“Vitamin A” on pg. 6). Gandia et al. teach forms of zinc to be delivered orally, including zinc bisglycinate (Title). Gandia et al. further teach zinc bisglycinate being a safe and well tolerated form of zinc with excellent bioavailability (Pg. 247 right column last paragraph). Therefore, it would have been prima facie obvious to a person having ordinary skill in the art before the effective filing date of the claimed invention to have modified the composition of Shade et al. to include zinc bisglycinate as taught by Gandia et al. It would have been obvious to combine the known oral supplement composition with the known use of zinc bisglycinate as an oral supplement to yield the predictable result of an oral supplement with improved bioavailability of vitamin B9 and vitamin A, with a reasonable expectation of success. As such, claims 9-10 are rejected as prima facie obvious. Claim 11 is drawn to the composition of claim 9, wherein the concentration of the zinc salt is in the range of 0.01 to 0.2% by weight based on the total weight of the liquid composition and calculated as elemental zinc. Gandia et al. further teach 7.5mg of zinc bisglycinate as a suitable amount of zinc bisglycinate for a single dose (Pg. 244 right column second paragraph), corresponding to 2.3 mg of elemental zinc as calculated by examiner. Shade et al. further teach the composition of examples 1-2 as being the amounts of a single dose of the oral supplement (Example 3 in col. 9). Inclusion of 7.5 mg of zinc bisglycinate in the composition of Shade et al. results in a composition comprising 0.07% by weight based on the total weight of the liquid composition and calculated as elemental zinc, overlapping with the instantly claimed range. Therefore, it would have been prima facie obvious to a person having ordinary skill in the art before the effective filing date of the claimed invention to include zinc bisglycinate in the composition of Shade et al. in the amount of 7.5 mg as taught by Gandia et al. It would have been obvious to combine the known supplement composition with the known amount of zinc suitable for a single dose to yield the predictable result of a supplement composition with a suitable dose of zinc. As such, claim 11 is rejected as prima facie obvious. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Paul Hoerner whose telephone number is (571)270-0259. The examiner can normally be reached Monday - Friday 9:00am - 5:00pm eastern. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bethany Barham can be reached at (571)272-6175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PAUL HOERNER/Examiner, Art Unit 1611 /CRAIG D RICCI/Primary Examiner, Art Unit 1611
Read full office action

Prosecution Timeline

Apr 17, 2024
Application Filed
Jan 10, 2025
Response after Non-Final Action
Oct 19, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12772979
HERBICIDAL N-HETEROARYL PYRAZOLE COMPOUNDS
3y 5m to grant Granted Oct 27, 2026
Patent 12758503
Pharmaceutical Formulation Comprising Cibenzoline or Salt Thereof
4y 4m to grant Granted Oct 13, 2026
Patent 12734135
CURCUMINOID COMPOSITIONS
5y 7m to grant Granted Sep 15, 2026
Patent 12735422
IMIDAZO-PYRIMIDONE COMPOUNDS AS PESTICIDES
3y 11m to grant Granted Sep 15, 2026
Patent 12702713
SEMI-SOLID, OIL-BASED PHARMACEUTICAL COMPOSITIONS CONTAINING PIRFENIDONE FOR APPLICATION IN TISSUE REPAIR
4y 11m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
51%
Grant Probability
99%
With Interview (+62.3%)
3y 8m (~1y 1m remaining)
Median Time to Grant
Low
PTA Risk
Based on 83 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month